<DOC>
	<DOCNO>NCT02832323</DOCNO>
	<brief_summary>Patients hemodialysis treatment mostly treat erythropoietin ( EPO ) erythropoiesis stimulate agent ( ESA ) . The objective ESA treatment maintain hemoglobin level therapeutic target around 11g/dl . The EPO dose necessary reach target depend numerous imbricated factor age , associate pathology , iron status , inflammation . As today , marker predict EPO response Hemoglobin ( Hb ) level currently late tool ass efficacy .</brief_summary>
	<brief_title>Interest Peak Reticulocytes Chronic Hemodialysis Patients Treated Mircera Hemodialysis Population</brief_title>
	<detailed_description>Reticulocytes immature red blood cell temporary present blood circulation . They easily monitor every automatic dosing machine . Nevertheless , among dialysis population , seldom use attempt define normal reticulocyte level , attest correct medullar response administrate EPO dose fail due time blood collection ( correspond Nadir day reticulocytosis ) . In preliminary study , show reticulocyte count kinetics depend ESA 's type , dose administration frequency . Reticulocyte kinetics compare three group stable dialysis patient , depend ESA treatment . Reticulocyte curve monthly Mircera® treatment different ESAs , show high reticulocyte peak ( av . 80 000 reticulocyte/ml ) occur Day ( D ) 8-D10 Mircera® administration . On contrary , nadir 's point ( D20-D30 injection ) , reticulocyte level low patient , prevent interpretation reticulocyte level monthly routine assessment . It look though peak level reticulocyte use marker ESA response . Therefore , monitor reticulocyte would support therapeutic decision need adapt EPO dose . The study design determinated interest reticulocyte peak daily practice</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Age &gt; equal 18 year Patients hemodialysis hemodiafiltration least 3 month Patient treat monthly Mircera® least one month Affiliate enjoy social security scheme Patients receive oral write information study , objection use personal data sign informed consent form write Patient refuse give write consent study Patients treat another Erythropoiesis stimulate agent Minor Pregnant breastfeed woman Major guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>EPO</keyword>
	<keyword>MIRCERA</keyword>
</DOC>